Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinoma.

Zhao WS, Yan WP, Chen DB, Dai L, Yang YB, Kang XZ, Fu H, Chen P, Deng KJ, Wang XY, Xie XW, Chen HS, Chen KN.

Am J Cancer Res. 2019 Jun 1;9(6):1183-1200. eCollection 2019.

PMID:
31285951
Free PMC Article
2.

TPL2 Kinase Is a Crucial Signaling Factor and Mediator of NKT Effector Cytokine Expression in Immune-Mediated Liver Injury.

Vyrla D, Nikolaidis G, Oakley F, Perugorria MJ, Tsichlis PN, Mann DA, Eliopoulos AG.

J Immunol. 2016 May 15;196(10):4298-310. doi: 10.4049/jimmunol.1501609. Epub 2016 Apr 6.

3.

JUNB/AP-1 controls IFN-γ during inflammatory liver disease.

Thomsen MK, Bakiri L, Hasenfuss SC, Hamacher R, Martinez L, Wagner EF.

J Clin Invest. 2013 Dec;123(12):5258-68. doi: 10.1172/JCI70405. Epub 2013 Nov 8.

4.

Stimulation of TRAF6/TAK1 degradation and inhibition of JNK/AP-1 signalling by ginsenoside Rg3 attenuates hepatitis B virus replication.

Kang LJ, Choi YJ, Lee SG.

Int J Biochem Cell Biol. 2013 Nov;45(11):2612-21. doi: 10.1016/j.biocel.2013.08.016. Epub 2013 Sep 1.

PMID:
24004833
5.

Expression of junB is markedly stimulated by glycyrrhizin in a human hepatoma cell line.

Koike K.

Oncol Rep. 2011 Mar;25(3):609-17. doi: 10.3892/or.2011.1137. Epub 2011 Jan 10. Erratum in: Oncol Rep. 2014 Feb;31(2):1030.

PMID:
21225234
6.
7.

Supplemental Content

Loading ...
Support Center